Mourad W A, Setrakian S, Hales M L, Abdulla M, Trucco G
Department of Pathology, University of Alberta, Edmonton, Canada.
Cancer. 1994 Sep 15;74(6):1739-45. doi: 10.1002/1097-0142(19940915)74:6<1739::aid-cncr2820740616>3.0.co;2-t.
Two interphase argyrophilic nucleolar organizer region (AgNOR) counts have been correlated with ploidy and proliferative activity in patients with ductal carcinoma in situ (DCIS) of the breast. The first is the mean number of AgNORs (mAgNOR); it reflects ploidy. The second is the percentage of nuclei with greater than or equal to five AgNORs/nucleus (pAgNOR); it correlates with proliferative activity. DCIS of the breast is a heterogeneous group of lesions that is not associated uniformly with invasive ductal carcinoma. A significant number of patients with DCIS will, however, progress to invasive ductal carcinoma. Factors identifying the invasive potential of DCIS in these patients have not been defined clearly. The authors postulated that pAgNOR in DCIS may predict the invasive potential of these lesions.
The authors studied 86 cases of DCIS of the breast by the AgNOR silver stain using the two above-mentioned counts.
There were 54 comedo and 32 noncomedo DCIS cases. Forty-one cases (47%) were associated with invasive ductal carcinoma. Thirty cases of comedo DCIS (55%) showed mAgNOR counts suggestive of aneuploidy (> or = 2.4/nucleus), whereas only seven cases of noncomedo DCIS (22%) showed such counts (P = 0.001). Cases associated with invasion had higher incidence of aneuploid mAgNOR counts (P = 0.0003). The pAgNOR counts in comedo DCIS ranged from 1% to 36% (median, 11%), whereas in noncomedo DCIS pAgNOR counts ranged from 0% to 22% (median, 7%) (P = 0.007). The 41 cases associated with invasion had pAgNOR counts ranging from 3% to 36% (median, 12%), whereas those not associated with invasion had pAgNOR counts ranging from 0% to 24% (median, 5%) (P = 0.000001). This difference was irrespective of the type of DCIS or mAgNOR counts.
Comedo DCIS of the breast may show a higher incidence of aneuploidy and increased proliferative activity and invasive ductal carcinoma than does noncomedo DCIS. Ploidy and proliferative activity, measured by AgNOR staining in DCIS, may have a significant predictive value in identifying the invasive potential of these lesions.
乳腺导管原位癌(DCIS)患者的两个间期嗜银核仁组织区(AgNOR)计数与倍体及增殖活性相关。第一个是AgNOR的平均数(mAgNOR),它反映倍体情况。第二个是核中AgNOR数大于或等于5个的细胞核百分比(pAgNOR),它与增殖活性相关。乳腺DCIS是一组异质性病变,并非均与浸润性导管癌相关。然而,相当数量的DCIS患者会进展为浸润性导管癌。明确这些患者中DCIS浸润潜能的相关因素尚未明确界定。作者推测DCIS中的pAgNOR可能预测这些病变的浸润潜能。
作者使用上述两种计数方法,通过AgNOR银染对86例乳腺DCIS病例进行研究。
有54例粉刺型和32例非粉刺型DCIS病例。41例(47%)与浸润性导管癌相关。30例粉刺型DCIS(55%)的mAgNOR计数提示非整倍体(≥2.4/细胞核),而只有7例非粉刺型DCIS(22%)有此类计数(P = 0.001)。与浸润相关的病例中非整倍体mAgNOR计数的发生率更高(P = 0.0003)。粉刺型DCIS的pAgNOR计数范围为1%至36%(中位数为11%),而非粉刺型DCIS的pAgNOR计数范围为0%至22%(中位数为7%)(P = 0.007)。41例与浸润相关的病例中pAgNOR计数范围为3%至36%(中位数为12%),而那些与浸润无关的病例中pAgNOR计数范围为0%至24%(中位数为5%)(P = 0.000001)。这种差异与DCIS的类型或mAgNOR计数无关。
乳腺粉刺型DCIS可能比非粉刺型DCIS表现出更高的非整倍体发生率、更高的增殖活性及浸润性导管癌发生率。通过在DCIS中进行AgNOR染色测量的倍体及增殖活性,在识别这些病变的浸润潜能方面可能具有重要的预测价值。